NIKI Stock Forecast: Niki Biosolutions, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.60
−4.76% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 9 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$5.2M
Ticker Nerd rank
9/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$825K
Net income−$311K
Free cash flow−$536K
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.0%
1M
−21.2%
YTD
−84.9%
1Y
−88.8%
From 52W high
−88.8%
From 52W low
+6.7%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Niki Biosolutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
9/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
65
Volatility
33
Accruals
28
Issuance
21
Revisions
20
Quality
14
Momentum
4
Value
2

Growth (65): Sales and profits are climbing, and climbing faster than before.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NIKI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NIKI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26NIKI

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Oct 2022HC Wainwright & Co.InitiatesBuy$8.00
2 Apr 2019China RenaissanceInitiatesBuy$22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NIKI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NIKI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Niki Biosolutions, Inc. returned −88.8% against +6.9% for the S&P 500, dividends included.

NIKI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26NIKIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NIKI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.1×

Cheaper than 97% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−17.1%

Higher than 33% of US stocks

Return on assets
−10.0%

Higher than 26% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Niki Biosolutions, Inc. has a market value of $5.2M.

  • Shares outstanding: 814,375.

  • Niki Biosolutions, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

NIKI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NIKINiki Biosolutions, Inc.$5.2M9
ICUSeastar Medical Holding Corp.$5.0M26
CDIOCardio Diagnostics Holdings, Inc.$4.7M20
SNGXSoligenix, Inc.$5.1M26
PULMPulmatrix, Inc.$4.6M47
CNSPCNS Pharmaceuticals, Inc.$5.2M15
SNTISenti Biosciences Holdings, Inc.$4.6M33

Take a look at NIKI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Niki Biosolutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NIKI

How does Ticker Nerd's model rank NIKI?

As at 21 Nov 2026, Niki Biosolutions, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (65 of 100).

What is the NIKI stock forecast for 2030?

No analyst covering Niki Biosolutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NIKI are extrapolating price history, which says nothing about the business.

How has NIKI stock performed over the past year?

Niki Biosolutions, Inc. returned -88.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Niki Biosolutions, Inc. do?

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease.

Company

About Niki Biosolutions, Inc.

Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for oncology and infectious diseases. Its current pipeline includes repurposed drug candidates and small molecules under clinical and preclinical evaluation, with programs aimed at treating neuroblastoma, bacterial infections, and coronavirus disease. The company also works on additional therapeutic assets targeting unmet medical needs across cancer and infectious disease areas. Based in Princeton, New Jersey, Niki BioSolutions operates through subsidiaries and maintains a product portfolio centered on drug development and translational research. Its role in the financial market reflects that of a specialized biotechnology issuer tied to early-stage clinical progress and pipeline advancement.

CEO Mr. Chung Yuen Huen · 1 employees · United States · https://www.aptorumgroup.com